Apolomics Inc.

Apolomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. It specializes in innovative product candidates designed to harness the immune system and target specific molecular pathways to inhibit cancer, with potential for combination with other treatment options. The company's pipeline includes late-stage clinical assets such as vebreltinib (APL-101), a potent, selective c-Met inhibitor for non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in Phase 2 trials, and uproleselan (APL-106), an E-Selectin antagonist for use with chemotherapy in acute myeloid leukemia and hematologic cancers, in Phase 1 and Phase 3 trials in China. Additional candidates like APL-102, a multiple tyrosine kinase inhibitor, are in early clinical stages. Apolomics Inc. addresses unmet medical needs in difficult-to-treat cancers through its broad portfolio across multiple oncology programs. Founded in 2015 and headquartered in Foster City, California, with operations extending to Taipei, Taiwan, the company operates under the guidance of experienced leadership in biotechnology and pharmaceuticals.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Hung-Wen Chen

Employees

14

Headquarters

Foster City, CA, United States

Website

www.apollomicsinc.com